![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-5503
Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.630, 2011-01, pp. : 13-13
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Dutasteride chemoprevention worth it for prostate cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 637, 2011-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Recent Approaches in Chemoprevention of Prostate Cancer
Current Cancer Drug Targets, Vol. 7, Iss. 7, 2007-11 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Prostate cancer chemoprevention: value rises with risk
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 606, 2010-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Wang Zhijun Fan Jeffery Liu Mandy Yeung Steven Chang Andy Chow Moses SS Pon Doreen Huang Ying
Expert Opinion on Investigational Drugs, Vol. 22, Iss. 12, 2013-12 ,pp. :